JP2013504301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504301A5 JP2013504301A5 JP2011545744A JP2011545744A JP2013504301A5 JP 2013504301 A5 JP2013504301 A5 JP 2013504301A5 JP 2011545744 A JP2011545744 A JP 2011545744A JP 2011545744 A JP2011545744 A JP 2011545744A JP 2013504301 A5 JP2013504301 A5 JP 2013504301A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- recombinant
- amino acids
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 32
- 241000191967 Staphylococcus aureus Species 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 claims description 8
- 102000036072 fibronectin binding proteins Human genes 0.000 claims description 8
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 claims description 7
- 101710096749 Penicillin-binding protein 2A Proteins 0.000 claims description 6
- 241000191940 Staphylococcus Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 4
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 4
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 4
- 102000006635 beta-lactamase Human genes 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 229920001184 polypeptide Polymers 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 239000000232 Lipid Bilayer Substances 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 229940027941 immunoglobulin g Drugs 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- 238000003780 insertion Methods 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 210000000170 cell membrane Anatomy 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000002949 hemolytic effect Effects 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 239000013554 lipid monolayer Substances 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 1
- 239000002052 molecular layer Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 101710198480 Clumping factor A Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09150888.7 | 2009-01-19 | ||
| EP09150888A EP2208787A1 (en) | 2009-01-19 | 2009-01-19 | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| PCT/EP2010/050453 WO2010081875A1 (en) | 2009-01-19 | 2010-01-15 | A recombinant alpha-hemolysin polypeptide of staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504301A JP2013504301A (ja) | 2013-02-07 |
| JP2013504301A5 true JP2013504301A5 (OSRAM) | 2013-03-21 |
| JP5781941B2 JP5781941B2 (ja) | 2015-09-24 |
Family
ID=40811673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011545744A Expired - Fee Related JP5781941B2 (ja) | 2009-01-19 | 2010-01-15 | ステムドメインにおける欠失および挿入された異種配列を有する黄色ブドウ球菌の組換えα溶血素ポリペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8545853B2 (OSRAM) |
| EP (2) | EP2208787A1 (OSRAM) |
| JP (1) | JP5781941B2 (OSRAM) |
| AU (1) | AU2010205645B2 (OSRAM) |
| CA (1) | CA2749862C (OSRAM) |
| ES (1) | ES2483720T3 (OSRAM) |
| WO (1) | WO2010081875A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010119343A2 (en) | 2009-04-14 | 2010-10-21 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| WO2012109167A1 (en) | 2011-02-08 | 2012-08-16 | Integrated Biotherapeutics, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| US9527905B2 (en) * | 2011-02-08 | 2016-12-27 | Medimmune, Llc | Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use |
| ES2864764T3 (es) | 2011-05-11 | 2021-10-14 | Childrens Medical Center | Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma |
| US10228347B2 (en) | 2011-06-24 | 2019-03-12 | Electronic Biosciences, Inc. | High contrast signal to noise ratio device components |
| CN102977214B (zh) * | 2012-09-29 | 2014-03-12 | 重庆原伦生物科技有限公司 | 用于耐甲氧西林金黄色葡萄球菌（mrsa）疫苗的重组蛋白hf2及制备方法和应用 |
| US10047129B2 (en) * | 2012-12-20 | 2018-08-14 | Electronic Biosciences, Inc. | Modified alpha hemolysin polypeptides and methods of use |
| EP4272750A3 (en) | 2013-02-07 | 2024-01-24 | Children's Medical Center, Corp. | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| ES2769647T3 (es) * | 2014-03-26 | 2020-06-26 | Glaxosmithkline Biologicals Sa | Antígenos estafilocócicos mutantes |
| CA2962241A1 (en) * | 2014-09-29 | 2016-04-07 | Fujifilm Corporation | Antibody-binding polypeptide, antibody-binding fusion polypeptide, and adsorption material |
| CN105641689B (zh) * | 2016-01-21 | 2024-09-10 | 浙江海隆生物科技股份有限公司 | 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用 |
| WO2018015575A1 (en) | 2016-07-22 | 2018-01-25 | Evaxion Biotech Aps | Chimeric proteins for inducing immunity towards infection with s. aureus |
| US11305001B2 (en) | 2017-03-28 | 2022-04-19 | The Children's Medical Center Corporation | Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof |
| CN111065417B (zh) | 2017-06-23 | 2024-04-19 | 美商艾芬尼维克斯公司 | 免疫原性组合物 |
| WO2020023644A2 (en) | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
| PE20211112A1 (es) | 2018-09-12 | 2021-06-22 | Affinivax Inc | Vacunas neumococicas multivalentes |
| SG11202101973YA (en) | 2018-09-12 | 2021-03-30 | Childrens Medical Ct Corp | Pneumococcal fusion protein vaccines |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
| WO2023039223A1 (en) | 2021-09-09 | 2023-03-16 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
| WO2024168197A2 (en) * | 2023-02-08 | 2024-08-15 | The Regents Of The University Of California | Membrane translocation compositions and methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999005167A1 (en) * | 1997-07-25 | 1999-02-04 | University Of Massachusetts | Designed protein pores as components for biosensors |
| US6355625B1 (en) | 1998-09-14 | 2002-03-12 | Nabi | Compositions of β-glucans and specific IGIV |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| AU2001292674A1 (en) * | 2000-09-15 | 2002-04-29 | University Of Connecticut Health Center | Improved formulations using heat shock/stress protein-peptide complexes |
| GB0107661D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| AU2003260357B2 (en) * | 2002-08-02 | 2009-10-29 | Glaxosmithkline Biologicals S.A. | Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis |
| JP2008513406A (ja) * | 2004-09-22 | 2008-05-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| EP2719397A1 (en) | 2006-06-12 | 2014-04-16 | GlaxoSmithKline Biologicals SA | Use of alpha-toxin for treating and preventing staphylococcus infections |
-
2009
- 2009-01-19 EP EP09150888A patent/EP2208787A1/en not_active Withdrawn
-
2010
- 2010-01-15 WO PCT/EP2010/050453 patent/WO2010081875A1/en not_active Ceased
- 2010-01-15 ES ES10700742.9T patent/ES2483720T3/es active Active
- 2010-01-15 CA CA2749862A patent/CA2749862C/en not_active Expired - Fee Related
- 2010-01-15 JP JP2011545744A patent/JP5781941B2/ja not_active Expired - Fee Related
- 2010-01-15 EP EP10700742.9A patent/EP2382316B1/en not_active Not-in-force
- 2010-01-15 AU AU2010205645A patent/AU2010205645B2/en not_active Ceased
- 2010-01-15 US US13/143,795 patent/US8545853B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013504301A5 (OSRAM) | ||
| Ord et al. | A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein | |
| Nilvebrant et al. | The albumin-binding domain as a scaffold for protein engineering | |
| JP5781941B2 (ja) | ステムドメインにおける欠失および挿入された異種配列を有する黄色ブドウ球菌の組換えα溶血素ポリペプチド | |
| Mann et al. | Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid–CbpA peptide recombinant fusion protein | |
| CN103890174B (zh) | IgG结合性肽及利用其检测和纯化IgG的方法 | |
| Yi et al. | Protection of Nile tilapia (Oreochromis niloticus L.) against Streptococcus agalactiae following immunization with recombinant FbsA and α-enolase | |
| JP2014506132A5 (OSRAM) | ||
| May et al. | Identification of fibronectin-binding proteins in Mycoplasma gallisepticum strain R | |
| JP2011523550A5 (OSRAM) | ||
| CN104844712B (zh) | 肺炎链球菌蛋白抗原及其制备方法和应用 | |
| Kumar et al. | Structural analysis and cross-protective efficacy of recombinant 87 kDa outer membrane protein (Omp87) of Pasteurella multocida serogroup B: 2 | |
| CN102892885A (zh) | IgA结合性肽以及利用其的IgA的纯化 | |
| JP2008530037A (ja) | 表面に位置したＳｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅのポリペプチド | |
| JP2016501266A5 (OSRAM) | ||
| Zhang et al. | Prevalent distribution and conservation of Streptococcus suis Lmb protein and its protective capacity against the Chinese highly virulent strain infection | |
| RU2016129526A (ru) | Антитело, выделенная нуклеиновая кислота, выделенный паратоп антитела, выделенный конформационный эпитоп, связывающая молекула, иммуноген, фармацевтический и диагностический препараты, лекарственная форма вакцины, способ лечения больного, подверженного риску или страдающего от инфекции Staphylococcus aureus, способ диагностики обнаружения инфекций Staphylococcus aureus и способ скрининга или анализа для определения связующего | |
| Khan et al. | IgY‐binding peptide screened from a random peptide library as a ligand for IgY purification | |
| Loisel et al. | Biochemical characterization of the histidine triad protein PhtD as a cell surface zinc-binding protein of pneumococcus | |
| Smidt et al. | Comprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance model | |
| Reese et al. | Purification of animal immunoglobulin G (IgG) using peptoid affinity ligands | |
| Walczak et al. | Method for generation of peptide‐specific igy antibodies directed to Staphylococcus aureus extracellular fibrinogen binding protein epitope | |
| JP7643730B2 (ja) | ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）プロテインＡ（ＳｐＡ）変種を含む方法および組成物 | |
| CN101987866B (zh) | 金黄色葡萄球菌Efb蛋白C端抗原表位及其制备方法和用途 | |
| Schennings et al. | Protective immunization against S taphylococcus aureus infection in a novel experimental wound model in mice |